Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 24, Pages 3832-3842
Publisher
American Society of Hematology
Online
2014-04-08
DOI
10.1182/blood-2013-12-543736
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Inflammatory neovascularization during graft-versus-host disease is regulated by v integrin and miR-100
- (2013) F. Leonhardt et al. BLOOD
- Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease
- (2013) S. Dong et al. BLOOD
- The Nlrp3 inflammasome regulates acute graft-versus-host disease
- (2013) Dragana Jankovic et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
- (2012) Paul J. Martin et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- IFN R signaling mediates alloreactive T-cell trafficking and GVHD
- (2012) J. Choi et al. BLOOD
- STAT3 Transcription Factor Promotes Instability of nTreg Cells and Limits Generation of iTreg Cells during Acute Murine Graft-versus-Host Disease
- (2012) Arian Laurence et al. IMMUNITY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen
- (2011) B. C. Betts et al. BLOOD
- Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): Early role for STAT1 and STAT3
- (2011) Hui-Hui Ma et al. CELLULAR IMMUNOLOGY
- Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice
- (2011) Huihui Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- The best endpoint for acute GVHD treatment trials
- (2010) M. L. MacMillan et al. BLOOD
- Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
- (2010) Konrad Wilhelm et al. NATURE MEDICINE
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
- (2009) Mary G. Boy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Graft-versus-host disease
- (2009) James LM Ferrara et al. LANCET
- IL-17 contributes to CD4-mediated graft-versus-host disease
- (2008) L. W. Kappel et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started